Apolipoprotein A-I (APOA1) Protein

Name: Apolipoprotein A-I (APOA1)

Synonyms: APOA1, MGC117399, Sep2, Alp-1, Ltw-1, Sep-1, Sep-2, Apoa-1, Brp-14, Lvtw-1, MGC102525, apoA-I, apoa, cb49, MGC103718, wu:fb33f01, zgc:103718, MGC64335, ApoA1, MGC89745, apoa-i, LOC100009253, ApoA-I, LOC100136573, apoa1

Protein Type: Recombinant

Source: Escherichia Coli (E. coli)

Origin (Gene): Human

Application: Western Blotting (WB), ELISA, Functional Studies (Func)

Catalog no.: ABIN413013

Additional Information

Gene ID: 335

NCBI Acession: NM_000039

Endotoxin Level: <0.1 ng/µg

Description: ApoA-I is a 29.0 kDa protein produced in the liver and intestine, and secreted as the predominant constituent of nascent high-density lipoprotein (HDL) particle. ApoA-I, which is found exclusively in HDL, has a unique ability to capture and solubilize free cholesterol. This apoA-I ability enables HDL to remove excess peripheral cholesterol and return it to the liver for recycling and excretion. This process, called reverse cholesterol transport, is though to inhibit atherogenesis. For this reason HDL is also known as the “good cholesterol.” The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I (called apoA-I Milano). The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic Vascular diseases. Recombinant human ApoA-I is a 28.2 kDa protein of 244 amino acid residues.
Synonyms: APOA1, MGC117399, Apoa1, Alp-1, Apoa-1, Brp-14, Ltw-1, Lvtw-1, MGC102525, Sep-1, Sep-2, Sep2, Human ApoA-1, ApoA-1, ApoA1, Apo A1, h-ApoA-1, rh-ApoA-1, recombinant human ApoA-1, ApoA1,recombinant ApoA-1, Apo, ApoA1, Apolipoprotein A-I, Apolipoprotein AI, Apolipoprotein

Molecular Weight: 28.2 kDa

Synonyms: APOA1, MGC117399, Sep2, Alp-1, Ltw-1, Sep-1, Sep-2, Apoa-1, Brp-14, Lvtw-1, MGC102525, apoA-I, apoa, cb49, MGC103718, wu:fb33f01, zgc:103718, MGC64335, ApoA1, MGC89745, apoa-i, LOC100009253, ApoA-I, LOC100136573, apoa1

Application Details

Handling Advice: Centrifuge the vial prior to opening.

Purity: >97% by SDS-PAGE and HPLC analyses Endotoxin level is <0.1 ng per μ g of ApoA-I.

Buffer: Sterile filtered and lyophilized

Storage: -20°C.
Stability: 12 months

Restrictions: For Research Use only

Publications

Product: Barlic, Zhu, Murphy: "Atherogenic lipids induce high-density lipoprotein uptake and cholesterol efflux in human macrophages by up-regulating transmembrane chemokine CXCL16 without engaging CXCL16-dependent cell adhesion." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 182, Issue 12, pp. 7928-36, 2009 (PubMed).

Saeed, Otsuka, Polavarapu et al.: "Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis." in: Arteriosclerosis, thrombosis, and vascular biology, Vol. 32, Issue 2, pp. 299-307, 2012 (PubMed).